Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 21; no. 2; pp. 162 - 170
• Main Authors: Kruse-Jarres, R., St-Louis, J., Greist, A., Shapiro, A., Smith, H., Chowdary, P., Drebes, A., Gomperts, E., Bourgeois, C., Mo, M., Novack, A., Farin, H., Ewenstein, B.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.03.2015; Wiley Subscription Services, Inc
• Subjects: acquired haemophilia A; Adult; Aged; Aged, 80 and over; Animals; Antibodies, Neutralizing; Autoantibodies; Autoantibodies - immunology; Bleeding; bleeding episodes; Coagulation factors; Cross Reactions - immunology; Dosage; Factor VIII - administration & dosage; Factor VIII - adverse effects; Factor VIII - immunology; Factor VIII - therapeutic use; Female; Hemophilia; Hemophilia A - drug therapy; Hemophilia A - immunology; Humans; Hypersensitivity; Male; Middle Aged; recombinant FVIII porcine sequence; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Recombinant Proteins - immunology; Recombinant Proteins - therapeutic use; replacement therapy; Swine; Thrombocytopenia; Time Factors; Treatment Outcome; acquired haemophilia A; bleeding episodes; recombinant FVIII porcine sequence; replacement therapy

Summary Acquired haemophilia A (AHA) is a rare bleeding disorder caused by autoantibodies against human factor VIII (hFVIII). OBI‐1 is an investigational, B‐domain deleted, recombinant FVIII, porcine sequence, with low cross‐reactivity to anti‐hFVIII antibodies. Efficacy can be monitored with FVIII...